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Protocol
AbstrACt
Introduction Diarrhoeal disease is the second 
leading cause of death in children under 5 years 
globally, killing 525 000 annually. Australian 
Aboriginal and Torres Strait Islander (hereafter 
Aboriginal) children suffer a high burden of disease. 
Randomised trials in other populations suggest 
nitazoxanide accelerates recovery for children with 
Giardia, amoebiasis, Cryptosporidium, Rotavirus and 
Norovirus gastroenteritis, as well as in cases where 
no enteropathogens are found.
Methods and analysis This double blind, 1:1 
randomised, placebo controlled trial is investigating 
the impact of oral nitazoxanide on acute 
gastroenteritis in hospitalised Australian Aboriginal 
children aged 3 months to <5 years. Dosing is based 
on age-based dosing. The primary endpoint is the 
time to resolution of ‘significant illness’ defined as 
the time from randomisation to the time of clinical 
assessment as medically ready for discharge, or to 
the time of actual discharge from hospital, whichever 
occurs first. Secondary endpoints include duration of 
hospitalisation, symptom severity during the period of 
significant illness and following treatment, duration 
of rehydration and drug safety. Patients will be 
followed for medically significant events for 60 days. 
Analysis is based on Bayesian inference. Subgroup 
analysis will occur by pathogen type (bacteria, virus 
or parasite), rotavirus vaccination status, age and 
illness severity.
Ethics and dissemination Ethics approval has been 
granted by the Central Australian Human Research 
Ethics Committee (HREC-14–221) and the Human 
Research Ethics Committee of the Northern Territory 
Department of Health and Menzies School of Health 
Research (HREC2014-2172). Study investigators will 
ensure that the trial is conducted in accordance with 
the principles of the Declaration of Helsinki. Individual 
participant consent will be obtained. Results will be 
disseminated via peer-reviewed publication.
trial registration number ACTRN12614000381684.
IntroduCtIon 
Acute gastroenteritis is the leading cause of 
global childhood mortality and morbidity, 
and disproportionately affects those in 
resource-poor settings.1 The GEMS study2 
quantified the pathogen-specific burden of 
enteric disease in several high burden low-in-
come countries; in that study, infection with 
enterotoxigenic and enteropathogenic  Esch-
erichia coli in infants 0–11 months and Cryp-
tosporidium in toddlers 12–23 months was 
associated with an increased 60-day mortality. 
Australian Aboriginal children also experi-
ence a disproportionate burden of disease 
compared with non-Aboriginal children.3 
Although the introduction of rotavirus vacci-
nation in 2006 has reduced disease burden, 
vaccine effectiveness in Aboriginal children 
has been low compared with that observed 
in non-Aboriginal Australian children.4 
strengths and limitations of this study
 ► NICE-GUT is the first study in Australia to evaluate 
the impact of nitazoxanide on acute gastroenteritis 
in Aboriginal children.
 ► This pragmatic randomised control trial is based 
on Bayesian adaptive design, an innovative trial 
methodology that overcomes some of the limitations 
encountered in trials informed by frequentist design.
 ► While Bayesian adaptive trials are becoming 
increasingly popular, they are yet to be established 
and accepted as routine research practice.
 ► The investigator group will rapidly ensure translation 
of research findings into clinical practice and health 
policy.
 ► Loss to follow-up is likely to be encountered in this 
study.
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Gastroenteritis outbreaks are well described among 
Aboriginal children living in remote central and northern 
Australia. These epidemics place enormous strain on 
remote health clinics, aeromedical retrieval services and 
hospital facilities.5 6 An effective oral treatment for the 
management of gastroenteritis would have a substantial 
impact in this setting in reducing disease burden and 
potentially reducing sequelae associated with prolonged 
and recurrent intestinal infections such as malnutrition, 
stunting and cognitive impairment.7 8 Therefore, while 
disease prevention remains the long-term goal, effec-
tive treatment strategies are still needed to reduce the 
health, social and economic and impact of childhood 
gastroenteritis.
Nitazoxanide, a thiazolide antimicrobial developed 
in the 1980s, has been shown to have broad-spectrum 
in vitro and/or clinical activity against a wide range of 
enteric pathogens including Giardia, Entamoeba, Bacte-
roides, Clostridium, Cryptosporidium, Rotavirus and Noro-
virus.9–15 Nitazoxanide is administered orally, is heat 
stable, and has proven to be safe and well tolerated in 
children,9 making it suitable for use in remote and low 
resource settings. To date, clinical trials of nitazoxanide 
have been conducted in low and middle income coun-
tries, where data have emerged to support its empirical 
use for the treatment of acute gastroenteritis regardless 
of aetiology.9 Results of these trials cannot be automati-
cally extrapolated to our high-income (but high disease 
burden) setting.
Here we describe a clinical trial protocol to investigate if 
nitazoxanide is clinically beneficial for the empirical treat-
ment of acute gastroenteritis among Australian Aborig-
inal children. Clinical trials in high burden and often low 
resourced settings are challenging. It is important to strike 
a balance between gathering reliable data pertaining to 
relevant endpoints against the challenges of working with 
a disparate and culturally diverse population for whom 
English language literacy and understanding of research 
may be limited and in whom pragmatic public health solu-
tions are needed in a timely manner. By using the prin-
cipals of pragmatic trial design, cross-cultural working 
and a Bayesian adaptive statistical approach, this trial will 
provide timely, relevant data to inform the management 
of gastroenteritis in these children.
MEthods And AnAlysIs
design
NICE-GUT is a double-blind, randomised, placebo-con-
trolled efficacy trial of oral nitazoxanide in Aboriginal 
children hospitalised with acute gastroenteritis. The 
protocol for enrolment, intervention, end points and 
analysis are based on the principles of pragmatic trial 
design and Bayesian sample-size adaptation; see trial flow 
chart (figure 1) and trial events schedule (table 1).
study setting
The study is being conducted at The Royal Darwin 
Hospital and Alice Springs Hospital, the two principal 
hospitals serving the Northern Territory (NT) of Australia. 
Aboriginal people represent 30% of the population in 
the NT.16 Most of the NT is classified as extremely remote; 
hospitalisation frequently requires aeromedical retrieval. 
Diarrhoea is the most prevalent condition at admission 
among infants and young adults in the NT, occurring in 
around 300 admissions per 1000 Aboriginal population.3 
Epidemics of gastroenteritis are also well described in this 
population.5
objectives
The primary objective of the NICE-GUT trial is to deter-
mine whether empiric treatment with oral nitazoxa-
nide (NTZ), compared with placebo, reduces the duration 
of significant illness in Aboriginal children hospitalised 
for acute gastroenteritis.
outcomes
The primary outcome is ‘the time period of significant 
illness’, defined as the time from randomisation until either 
(1) the time to achieve a score ≥2 on the ‘medical readi-
ness for discharge’ scoring system (table 2) as assessed by 
the study doctor or study nurse or (2) the time to actual 
hospital discharge, except for children who die, abscond 
or are transferred to other health facilities, whichever is 
sooner. Assessment of medical readiness for discharge is 
based on medical factors only and specifically excludes 
social issues that may influence actual discharge decisions. 
Further details are provided under study procedures.
Secondary outcomes include (1) duration of hospi-
talisation, defined as the time from randomisation until 
actual discharge from hospital (including time after 
being assessed as medically suitable for discharge); (2) 
number of stools and vomiting episodes during the 
‘time period of significant illness’; (3) the presence and 
severity of symptoms from the time of randomisation to 
day 7, based on the number of vomits/diarrhoea, overall 
symptoms and activity level; (4) the presence and severity 
of dehydration based on WHO guidelines (online supple-
mentary appendix 1)17; and (5) the time between starting 
intravenous, intraosseous or nasogastric rehydration 
or randomisation (whichever occurs later) and ceasing 
rehydration.
Safety outcomes include adverse events attributed to the 
study drug, mortality at 60 days, recurrent gastroenteritis 
within 60 days of enrolment, new onset malnutrition (not 
pre-existing) requiring medical assessment/intervention 
within 60 days of enrolment and prolongation of symp-
toms beyond 7 days.
Participants
Potential participants are identified from review of ward 
admission logs, hospital information systems and by 
hospital clinical staff. A verbal overview of the study, aided 
by use of a study ‘flip-chart’ giving a pictorial outline of 
the study, is used to outline the study to the parent/
legally responsible carer of potential participants. A 
written information sheet is also provided. This approach 
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was informed by consultation with Aboriginal people. 
Administration of the study drug must occur within 
12 hours of all screening procedures.
Australian Aboriginal children aged ≥3 months and <5 
years hospitalised for less than 48 hours with a primary 
diagnosis of acute gastroenteritis (in the opinion of the 
admitting doctor or the study nurse) are eligible for enrol-
ment. Data exist regarding the safety of nitazoxanide in 
this age group,9 11 13 18–21 but not in infants <3 months 
old. Ethnicity is determined by self-report of the parent 
or legally responsible carer. Additional requirements for 
eligibility include permission by the parent to (1) notify 
healthcare practitioners involved in their child’s care 
about participation, (2) ascertain vaccination history 
from the Australian Immunisation Register and/or local 
provider, and (3) obtain medical data from the medical 
records and/or primary care provider. Exclusion criteria 
are (1) bloody diarrhoea (dysentery) or known infection 
with an enteric pathogen requiring alternative antimicro-
bial treatment, (2) clinical suspicion of a non-infectious 
aetiology or an intestinal obstruction, (3) contraindica-
tion or allergy to nitazoxanide, (4) previous enrolment, 
(5) symptom duration >14 days, (6) non-availability of 
oral route for drug administration.
study procedures
Baseline assessment
To assess eligibility and to allow description of the study 
population, demographic data (including number of 
co-inhabitants <5 years and ≥5 years old and number 
of bedrooms in the household), clinical details of 
current illness, past medical history (including rotavirus 
Figure 1 Trial flow chart. SAE, serious adverse events. 
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vaccination history), baseline bowel pattern, breastfeeding 
status and anthropometric indices (bare weight, length/
height mid-upper arm circumference) are gathered.
Randomisation, intervention and blinding
Randomisation of eligible participants is by computer 
generated allocation sequence, using randomly permuted 
block sizes, with stratification by age (<1 year vs ≥1 year 
old), hospital and remoteness of residence (urban 
Darwin or Alice Springs vs elsewhere in the NT) on the 
night prior to admission.
Participants are randomised 1:1 within the four strata 
to receive either nitazoxanide or placebo. The study drug 
is prescribed to be given within 12 hours of randomisa-
tion, with nitazoxanide dose determined by age-based 
dosing (<1 year olds: 7.5 mg/kg/dose; 1 to 3 years old: 
100 mg/dose; ≥4 years of age, 200 mg/dose) and admin-
istered twice daily for 3 days orally or by nasogastric/
enteric tube. If vomiting occurs within 15 min of adminis-
tration, the drug is re-administered. If the child vomits a 
second time, no further doses will be given. The placebo 
is physically and chemically identical to the intervention 
drug except it does not contain nitazoxanide. All investi-
gators, research staff and participants, except for the trial 
statistician, are blinded to the treatment allocation until 
study completion. Nitazoxanide is the standard treatment 
for refractory cryptosporidiosis in our setting. There is 
provision for unblinded nitazoxanide rescue therapy 
for participants with refractory cryptosporidiosis after 
discussion with the co-ordinating principal investigator. 
Transfer to rescue treatment does not require withdrawal 
of the participant from the study.
All aspects of patient management such as rehydration, 
management of ongoing losses and provision of oral/
enteral/parenteral diet and management of comorbidites 
(eg, hypokalaemia/hyperkalaemia or hypoglycaemia) are 
managed as per the instruction of the primary treating 
team in accordance with local guidelines.
Follow-up
Participants are reviewed by a study nurse twice daily 
(08:00+4 hours and 16:00+4 hours) during the first 7 days 
of hospitalisation to record symptoms (including number 
of diarrhoeal stools and vomiting episodes), activity 
level, hydration status, any adverse events and whether 
the child is medically ready for discharge (see table 2). 
Volume and route of re-hydration therapy and use of 
unblinded ‘rescue’ nitazoxanide are recorded once 
daily. A further assessment of readiness for discharge is 
requested of the ward nurses daily (0000+4 hours); if a 
child is judged medically ready for discharge by a ward 
nurse overnight, this is validated by a study nurse or study 
doctor the following morning.
Participants discharged from hospital prior to study 
day 7 are asked to complete an aide memoire diary 
card detailing administration of study drug and symp-
toms. Participants for whom phone contact cannot be 
made by day 10 are considered lost to follow-up, but 
remain enrolled. Participants who remain hospitalised 
at day 7 are followed daily until discharge to determine 
the reason for ongoing hospitalisation. Any new illness 
prolonging hospitalisation is reported as a serious adverse 
event (SAE).
At study day 30 and day 60, electronic hospital and 
primary care records are reviewed by a study nurse to 
ascertain the safety endpoints. The trial will end following 
completion of the last laboratory assay on the last partic-
ipant enrolled, or 60 days postrandomisation of the last 
participant, whichever is later.
Data collection
Relevant data are obtained from hospital and labora-
tory records, participant diaries, radiographs and clin-
ical correspondence. Data are recorded onto paper case 
report forms. Participants are followed up at day 7 after 
enrolment by a study nurse (by telephone if discharged) 
to ascertain symptoms. Once collected, data are entered 
onto a password protected electronic data capture system 
built in Medrio (mEDU Academic eClinical, 2017). Study 
documents will be stored securely at each study site and 
will be archived when the youngest participant reaches 25 
years of age.
Laboratory testing
A stool sample (>3 mL) is obtained as soon as possible 
after randomisation. Stools undergo wet preparation 
evaluation and routine bacterial culture on MacConkey 
and Xylose Lysine Deoxycholate agar as well as Campy-
lobacter-specific media. A blind sweep of the MacConkey 
agar plate is collected after 24 hours of incubation and 
inoculated onto dorset egg medium, incubated overnight 
at 37°C, and then at room temperature until transfer to 
the University of Melbourne for molecular testing for 
enterovirulent pathotypes of E. coli. Cryptosporidium  and 
Giardia are identified by rapid faecal antigen testing. 
Stool remaining after routine laboratory testing is frozen 
at < −70°C before being transferred to the Murdoch Chil-
dren’s Research Institute for testing for rotavirus and 
norovirus by PCR.
Other clinically indicated laboratory tests including 
blood culture, biochemistry and haematology are 
performed at the discretion of the treating team and 
according to standard hospital procedures.
Table 2 Medical readiness for discharge scoring system
Score
0 1 2 3
Not medically 
ready for 
discharge. 
Ongoing 
requirement 
for hospital 
level care
Not medically 
ready for 
discharge, 
but improved 
from 
condition at 
randomisation
Medically ready 
for discharge 
with suitable 
carer input, 
but not fully 
recovered
Medically 
ready for 
discharge, 
fully 
recovered
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Withdrawal of participants
Parents and legal carers have the right to withdraw their 
child from the trial at any time. The chief investigator 
(CI) or site principal investigator may elect to discon-
tinue participant involvement in the trial if (1) the child 
is found to be ineligible following recruitment, (2) signif-
icant protocol violations occur, (3) non-adherence with 
the treatment regimen or trial requirements occur, (4) 
adverse events arise requiring discontinuation of the trial 
medication, (5) withdrawal of consent occurs or (6) loss 
to follow-up occurs. Data obtained prior to participant 
withdrawal from the study will be included in the analysis.
data analyses and sample size justification
Participants are analysed according to the group they 
are randomised to (intention-to-treat analysis). All 
randomised participants with observed outcome data will 
be analysed in a secondary completers’ population anal-
ysis. Analyses are based on Bayesian inference; the statis-
tical model considers the evidence accumulated during 
the trial and the assumed prior knowledge (known 
as a prior distribution). The parameters in the model 
are assigned non-informative prior distributions. This 
approach was used to ensure the trial continued only as 
long as there remained reasonable uncertainty regarding 
the treatment effect, thereby aiding timely trial results, 
potentially accelerating implementation and minimising 
exposure to any risk and research burden. This method 
of statistical analysis differs from traditional frequentist 
trials in which inferences are based on the likelihood of 
different sample outcomes against a null hypothesis. In 
contrast, Bayesian analysis is done conditional on the 
observed data, but inference does not depend on either 
the sampling design or on outcomes that did not occur.
The variables for which adjustment are made are age 
group and remoteness. Outcomes for these strata are 
reported separately, but the model captures any common-
alities across strata. The statistical model allows evidence 
relating to the effectiveness of an intervention in one 
stratum to contribute (via ‘borrowing’) to the estimation 
of the posterior probability in the other strata, but this 
only occurs to the extent that the intervention effect is 
similar across different strata. The results of these anal-
yses are used to achieve the primary objective of the trial 
which is to determine the effectiveness of nitazoxanide 
and the extent to which that effectiveness varies between 
strata (intervention–stratum interaction).
A first interim analysis occurs after the 126th randomised 
child has recorded information for time of significant 
medical illness. If required, further interim analyses will 
occur as soon as practicable after every additional 20 chil-
dren enrolled (the 150th, 170th, 190th, 210th, 230th, 
250th, 270th and 300th enrolment). At each interim anal-
ysis, the Bayesian predictive probability that the time of 
significant medical illness is shorter with nitazoxanide 
treatment versus placebo is estimated for each stratum. 
The estimated probability for each stratum determines 
whether to
1. stop enrolment for futility (<20% or <40% probability 
for interim analyses 1–4 and 5–8, respectively, that ni-
tazoxanide shortens the duration of significant illness 
compared with placebo;
2. stop enrolment for success (>99% or >98% probability 
for interim analyses 1–4 and 5–8, respectively, that ni-
tazoxanide shortens the duration of significant illness 
compared with placebo;
3. continue enrolment due to uncertainty of effect 
(20%–99% or between 40% and 98% probability for 
interim analyses 1–4 and 5–8, respectively, that ni-
tazoxanide shortens the duration of significant illness 
compared with placebo.
If none of the stopping rules have been met after 300 
children have been enrolled, no further children will be 
enrolled and the nitazoxanide arm will be considered 
superior for the primary endpoint if there is >97.5% prob-
ability that this arm has a shorter time of significant 
medical illness compared with the placebo arm.
The comparison of the nitazoxanide and placebo 
arms for time to resolution of significant medical illness 
(primary outcome) is summarised by a hazard ratio (HR) 
and denoted by θd (or log transformed θd for the log 
HR). The hypothesis test for the comparison between 
nitazoxanide and placebo arms is
 H0 : θd ≤ 1(alternatively log(θd) ≤ 0) 
 H1 : θd > 1(alternatively log(θd) > 0) 
The log HR (treatment effect) is given a vague non-in-
formative prior, log(θ0d) ∼ N[0, 10] : in particular, the 
prior probability that nitazoxanide is beneficial is the 
same as the prior probability that it is futile. If there is 
a high posterior probability that the treatment effect, 
log θd, is positive, the treatment is declared to be effica-
cious. The posterior probability is conditional on the final 
results from all subjects enrolled in the trial.
The stopping rules for the primary analysis have been 
calibrated to ensure a one-sided experiment-wise type 
1 error rate of 0.05. All prespecified analyses will be 
reported in the main manuscript.
Subgroup analysis will occur according to pathogen 
group (bacteria, virus or parasite), rotavirus vaccina-
tion status, age (<1 and ≥1 year) and severity of illness at 
presentation (nil, mild, moderate or severe acidosis or 
dehydration) (online supplementary appendix 1 and 2).
Safety reporting and trial oversight
All SAEs are recorded from the time of enrolment until 
the 60-day follow-up, and are reported to the sponsor 
within one working day. All SAEs are reported to the 
approving ethics committees in accordance with their 
requirements. All suspected, unexpected serious adverse 
reactions are reported to the Australian Therapeutic 
Goods Administration by the sponsor within 7 days.
A Data and Safety Monitoring Committee convenes 
at least twice per year to provide safety oversight and to 
monitor the overall conduct of the trial including adher-
ence to stopping rules prespecified in the protocol.
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Randomisation codes are held by the trial statistician 
and password protected. Code breaks are only to be used 
if a situation arises where the CI deems it necessary to 
break the blinding process for compelling medical or 
safety reasons.
dIsCussIon
Despite the advent of rotavirus vaccination, gastro-
enteritis remains a significant health problem in Austra-
lian Aboriginal children, as well as in many resource-poor 
settings globally. Treatment that reduces the duration 
and severity of disease is needed to reduce the health, 
economical and societal burden of disease.
Clinical trials in remote populations and high disease 
burden settings present many logistical challenges. This 
protocol outlines our approach to meeting several of 
these challenges. Pragmatic clinical trials recognise that 
although randomisation, blinding and precise endpoints 
promote internal validity, they do not ensure external 
validity—that is, extrapolation of trial outcomes to popu-
lations and situations beyond the trial population. For 
trials such as this that seek to address important global 
health issues, it is essential that data are gathered in a way 
that facilitates extrapolation beyond the confines of the 
specific protocol and trial population.
In this trial, we are gathering a range of baseline data 
to allow full description of the study population and, 
where numbers permit, subgroup analyses that may 
inform the wider global health agenda. We selected 
a primary endpoint based on duration of significant 
illness (requiring hospitalisation) as the most important 
endpoint because of its relevance to patients, families, 
care providers and policy makers; we believe that it will 
be informative for other settings.
Other trials of nitazoxanide have restricted treatment to 
those with confirmed infection with one or more specific 
pathogens. For nitazoxanide to be broadly applicable for 
treatment of Aboriginal children, it will need to be used 
empirically, that is, before stool microbiology results are 
available. This is because awaiting stool results will delay 
commencement of therapy; because of these delays, chil-
dren with acute gastroenteritis treated remotely usually 
have no microbiology testing. Our eligibility criteria 
are very inclusive; we aim to include all children with 
presumed infective gastroenteritis except those children 
ineligible because of known or anticipated intolerance or 
where alternative therapy is indicated. We have prespec-
ified subgroups analyses based on age and remoteness 
because the spectrum of pathogens is somewhat different 
across these patient groups; detection of group-specific 
treatment effects could inform targeted treatment based 
on these factors.
Ensuring valid informed consent that meets the stan-
dards outlined in the Declaration of Helsinki is of para-
mount importance, especially in a vulnerable population 
in whom much historical research has resulted in little 
direct benefit. It can be difficult to ensure this in the 
context of low levels of health literacy and when working 
across cultures where concepts of individual versus 
community-level determination differ. We sought involve-
ment of an Aboriginal reference group to inform the 
study design and consent procedures.
Traditional ‘frequentist’ methods for analysing clin-
ical trials demand that the sample size be determined 
in advance, based on the expected treatment response 
rate among controls and a largely arbitrary decision 
about what constitutes a minimum clinically important 
difference. Such judgements are based on a ‘best guess’ 
approach, and consequently most trials either fail to 
answer the question they set out to address with certainty 
or, alternatively, continue to enrol participants far beyond 
the point where evidence of an effect has been reached. 
Adaptation of the sample size based on accumulated data 
and Bayesian inference, as used in this trial, will increase 
the probability of a conclusive result while ensuring 
that the trial does not continue beyond the point where 
either futility or success can be concluded. This will help 
minimise any risk and burden associated with research 
participation, ensure that the trial findings, if positive, are 
translated into practice in a timely fashion and expedite 
evaluation of alternative therapies if the trial results are 
negative.
EthICs And dIssEMInAtIon
Study investigators will ensure that this trial is conducted 
in accordance with the principles of the Declaration of 
Helsinki22 and with the ICH Guidelines for Good Clinical 
Practice.23
Dissemination of results will occur through peer-re-
viewed publications and presentation(s) to important 
stakeholders.
Earlier protocol versions
After 126 enrolments, before any analysis and while all 
investigators including the trial statistician remained 
blinded, a substantial amendment to the protocol was 
made due to slower than anticipated enrolment. In the 
earlier version of the trial protocol, the study procedures 
and endpoints were the same, except we planned for a 
single frequentist time-to-event analysis after a fixed 
sample size of 400 enrolments.
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